Massachusetts Financial Services Co. MA Grows Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

Massachusetts Financial Services Co. MA increased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCTFree Report) by 0.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,952,742 shares of the company’s stock after purchasing an additional 3,367 shares during the period. Massachusetts Financial Services Co. MA’s holdings in MaxCyte were worth $6,093,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of MXCT. BlackRock Inc. lifted its stake in shares of MaxCyte by 3.0% during the first quarter. BlackRock Inc. now owns 7,020,661 shares of the company’s stock worth $34,752,000 after buying an additional 205,579 shares during the period. Vanguard Group Inc. raised its holdings in shares of MaxCyte by 37.4% during the third quarter. Vanguard Group Inc. now owns 4,665,320 shares of the company’s stock worth $30,324,000 after purchasing an additional 1,269,810 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in shares of MaxCyte by 46.5% during the second quarter. Stonepine Capital Management LLC now owns 3,966,916 shares of the company’s stock worth $18,208,000 after purchasing an additional 1,259,826 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in shares of MaxCyte by 12.1% during the second quarter. ArrowMark Colorado Holdings LLC now owns 2,576,260 shares of the company’s stock worth $11,825,000 after purchasing an additional 277,186 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of MaxCyte by 67.3% during the second quarter. Millennium Management LLC now owns 2,355,086 shares of the company’s stock worth $11,140,000 after purchasing an additional 947,104 shares during the last quarter. 62.25% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Stock Performance

MXCT opened at $4.89 on Monday. MaxCyte, Inc. has a fifty-two week low of $2.45 and a fifty-two week high of $5.55. The company has a fifty day moving average of $4.93 and a two-hundred day moving average of $4.09. The stock has a market capitalization of $508.61 million, a price-to-earnings ratio of -13.22 and a beta of 1.44.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of MaxCyte in a report on Tuesday, January 9th. Craig Hallum began coverage on shares of MaxCyte in a report on Wednesday, November 29th. They issued a “buy” rating and a $7.00 price objective for the company.

Get Our Latest Report on MaxCyte

Insider Buying and Selling at MaxCyte

In other news, Director John Joseph Johnston sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $3.71, for a total transaction of $37,100.00. Following the completion of the sale, the director now owns 120,583 shares of the company’s stock, valued at $447,362.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director John Joseph Johnston sold 10,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $3.71, for a total transaction of $37,100.00. Following the completion of the sale, the director now owns 120,583 shares of the company’s stock, valued at $447,362.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas Doerfler sold 5,350 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $5.00, for a total transaction of $26,750.00. Following the sale, the chief executive officer now directly owns 333,197 shares of the company’s stock, valued at approximately $1,665,985. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,550 shares of company stock valued at $236,050. Corporate insiders own 6.00% of the company’s stock.

MaxCyte Profile

(Free Report)

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Featured Stories

Want to see what other hedge funds are holding MXCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MaxCyte, Inc. (NASDAQ:MXCTFree Report).

Institutional Ownership by Quarter for MaxCyte (NASDAQ:MXCT)

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.